Umbilical Cord Blood Hematopoietic Stem Cells

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Umbilical Cord Blood Hematopoietic Stem Cells
Accession Number
DB15723
Description

The use of umbilical cord blood (UCB) for therapies is advantageous because of its ease of access, non-invasive collection procedures, and more plasticity for multi-differentiation. UCB contains a large source of hematopoietic stem cells (HSCs) that are capable of self-renewal, have increased sensitivity to various factors, and are able to generate erythroid and myeloid progenitor colonies. Specifically, the proliferation capacity of human umbilical cord blood mononuclear progenitor cells (HUCBC) are much higher than similar cells in bone marrow. From the UCB, mononuclear cells are isolated and cultured in medium, expanded, and differentiated into the desired cell type.

HUCBC CD34+ cells are cultured with various cytokines and interleukins to give rise to various cell types, from red blood cells, to B-, T-, and Natural Killer Cells. The content of these cells depends and changes based on the gestational age. Because HUCBC are largely immature, do not express class II HLA antigens, and do not produce as many cytokines and immunoglobulins as adult lymphocytes, transplantation with these cells means low levels of cytotoxicity and immunological reactions.

Cord blood transplants have been used to treat conditions from aplastic anemia, B-thalassemia, X-linked lymphoproliferative syndrome, Hunter’s syndrome, acute lymphoid leukemia, chronic myeloid leukemia, to neuroblastoma. This highlights the adaptive nature of these cells.

Type
Biotech
Groups
Investigational
Biologic Classification
Cell transplant therapies
Other cell transplant therapies
Synonyms
  • Cord blood therapy
  • HUCBCs
External IDs
  • Umbilical Cord Blood Hematopoietic Stem Cells

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

The mononuclear cells originating from the hematopoietic stem cells in the umbilical cord blood are shown to have a higher immune tolerance in donors after transplants due to their immaturity and lack of class II HLA antigens. These cells are transplanted to treat various diseases, including hematological, oncological, cardiovascular, and even neurological-based pathologies. Currently, this type of therapy is being explored for the treatment of COVID-19 related effects.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Rallapalli S, Guhathakurta S, Narayan S, Bishi DK, Balasubramanian V, Korrapati PS: Generation of clinical-grade red blood cells from human umbilical cord blood mononuclear cells. Cell Tissue Res. 2019 Feb;375(2):437-449. doi: 10.1007/s00441-018-2919-6. Epub 2018 Oct 3. [PubMed:30284087]
  2. Aliyari Z, Alemi F, Brazvan B, Tayefi Nasrabadi H, Nozad Charoudeh H: CD26+ Cord Blood Mononuclear Cells Significantly Produce B, T, and NK Cells. Iran J Immunol. 2015 Mar;12(1):16-26. doi: IJIv12i1A2. [PubMed:25784094]
  3. Henning RJ, Abu-Ali H, Balis JU, Morgan MB, Willing AE, Sanberg PR: Human umbilical cord blood mononuclear cells for the treatment of acute myocardial infarction. Cell Transplant. 2004;13(7-8):729-39. doi: 10.3727/000000004783983477. [PubMed:15690974]
  4. Galieva LR, Mukhamedshina YO, Arkhipova SS, Rizvanov AA: Human Umbilical Cord Blood Cell Transplantation in Neuroregenerative Strategies. Front Pharmacol. 2017 Sep 8;8:628. doi: 10.3389/fphar.2017.00628. eCollection 2017. [PubMed:28951720]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on August 11, 2020 12:13 / Updated on August 13, 2020 01:02

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates